Back to School: How biopharma can reboot drug development. Access exclusive analysis here

How CART changed its horse

AtheroGenics Inc.'s CART-2 trial has gone through some evolutionary somersaults, and the company surprised everyone last week by disclosing preliminary rather than complete results. Nevertheless, the study adds one more piece of evidence that AGI-1067 reduces atherosclerotic plaque versus baseline. Most importantly, the interim data are comparable to data from recent atherosclerosis trials evaluating treatment methods such as statins.

The Phase IIb Canadian Antioxidant Restenosis Trial-2 (CART-2) was originally designed to evaluate

Read the full 722 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE